This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Infectious disease	<i>Caenorhabditis elegans</i> abnormal dauer formation (DAF-12)	<i>In vitro</i> studies suggest that DAF-12 ligands could help treat parasite infections. In cultured <i>Strongyloides stercoralis</i> , one such ligand—dafachronic acid—activated orthologs of DAF-12 and decreased the population of pathogenic larvae. Next steps include identification of a selective DAF-12 modulator and additional testing in animal models. SciBX 2(22); doi:10.1038/scibx.2009.914 Published online June 4, 2009	Patent filed covering technology; available for licensing	Wang, Z. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online May 25, 2009; doi:10.1073/pnas.0904064106 Contact: David J. Mangelsdorf, University of Texas Southwestern Medical Center, Dallas, Texas e-mail: davo.mango@utsouthwestern.edu